Efficacy and safety of ultra-long-acting insulin degludec
Therapeutic Advances in Endocrinology and Metabolism, 2012 All patients with type 1 diabetes and significant numbers of those with type 2 diabetes are treated with insulin. Nonadherence to insulin regimen can impact glycaemic control.
Ammar Wakil, Stephen L. Atkin
doaj +3 more sources
Insulin degludec is a new ultra-long-acting insulin analogue [PDF]
Сахарный диабет, 2014 Achieving optimal glycemic control is an important aspect of preventing and slowing the progression of diabetes-associated complications, and reducing the cost of their treatment.
Ivan Ivanovich Dedov +1 more
doaj +2 more sources
Budget Impact of Long-Acting Insulin Analogues: The Case in Brazil. [PDF]
PLoS ONE, 2016 BackgroundLong-acting insulin analogues for type 1 diabetes (T1D) treatment have been available on the Brazilian market since 2002. However, the population cannot access the analogues through the public health system.ObjectiveTo estimate the incremental ...
Fernanda O Laranjeira +2 more
doaj +2 more sources
A comparative study between topical short and long-acting insulin preparations in management of wounds in diabetic patients [PDF]
Journal of Advanced Biomedical and Pharmaceutical Sciences, 2021 Wounds of diabetic patients often require weeks of adequate and appropriate care for full recovery. The use of systemic insulin in diabetic patients was reported to enhance wound healing.
Ahmed Abdel-mawla +3 more
doaj +1 more source
Insulin glulisine in the management of diabetes
Diabetes, Metabolic Syndrome and Obesity, 2009 Satoru Yamada1,21Diabetes Center, Kitasato Institute Hospital, Tokyo, Japan; 2Department of Internal Medicine, Keio University School of Medicine, Tokyo, JapanAbstract: Insulin glulisine is appealing in principle, but the advantages of this drug over the
Satoru Yamada
doaj +1 more source
Cost-effectiveness of long-acting insulin analogues vs intermediate/long-acting human insulin for type 1 diabetes: A population-based cohort followed over 10 years. [PDF]
Br J Clin Pharmacol, 2020 Lee TY, Kuo S, Yang CY, Ou HT.
europepmc +2 more sources
Sakarya Tıp Dergisi, 2023 This study was designed to evaluate the box sale trends of insulin preparations and glucagon-like peptide-1 (Glp-1) analogs by their therapeutic categories in Turkey. Also, we aimed to project sale trends of these pharmaceuticals in next years.
Oğuzhan Yıldız +3 more
doaj +1 more source
The journey of insulin over 100 years
Journal of Diabetology, 2022 The year 2021 marks 100 years of insulin discovery. In 1921, Banting and Best identified the pancreas as a key organ mainly responsible for carbohydrate metabolism and pathogenesis of diabetes.
Jayshree Swain +3 more
doaj +1 more source
Metabolic implications when employing heavy pre- and post-exercise rapid-acting insulin reductions to prevent hypoglycaemia in Type 1 diabetes patients: a randomised clinical trial [PDF]
, 2014 Aim To examine the metabolic, gluco-regulatory-hormonal and inflammatory cytokine responses to large reductions in rapid-acting insulin dose administered prandially before and after intensive running exercise in male type 1 diabetes patients ...
Dunseath, G +69 more
core +1 more source
Management and efficacy of intensified insulin therapy starting in outpatients [PDF]
, 1989 Diabetic patients under multiple injection insulin therapy (i.e., intensified insulin therapy, IIT) usually start this treatment during hospitalization. We report here on the logistics, efficacy, and safety of IIT, started in outpatients.
Winkelmann, W. +11 more
core +1 more source